• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Bard: We’re on track for early 2015 Lutonix approval

Bard: We’re on track for early 2015 Lutonix approval

July 25, 2014 By Brad Perriello

Bard: We're on track for early 2015 Lutonix approval

C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.

Last month an FDA panel recommended that the watchdog agency approve the Lutonix device, which is designed to treat peripheral artery disease, voting unanimously that it is safe, effective and its benefits outweigh its risks.

John DeFord, Bard’s senior vice president of science, technology & clinical affairs, told analysts during a conference call yesterday that publication of the Levant 2 clinical trial comparing treatment with Lutonix to treatment with a non-drug-coated balloon is undergoing review at a "targeted journal."

"The authors informed us this week that they received communication from a targeted journal, which required revisions, as is typical in the process. The authors plan to respond in the coming weeks, and we’re pleased with the process and it’s moving forward, but we can’t predict the timing or the outcome here as it’s really outside of our control," DeFord said. "And though the panel was an important milestone, we’re focused on continuing to expand sizes and indications worldwide. We completed enrollment in our Levant 2 Japan study in June, and we expect to submit next year for approval."

Bard posted losses of -$119.4 million, or -$1.59 per share, on sales of $827.1 million during the 3 months ended June 30, paring losses by 26.1% on sales growth of 8.8% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $2.06, up 22.0% over Q2 2013 and a full nickel ahead of expectations on Wall Street.

"Once again we exceeded our expectations for revenue growth this quarter. We continue to believe that executing our investment plan will accelerate the sustainable growth rate of the overall portfolio and put us in a position to provide revenue growth in the mid-to-high single digits with attractive returns for shareholders," chairman & CEO Timothy Ring said in prepared remarks.

CFO Christopher Holland yesterday said that Bard is raising its full-year sales and earnings guidance. The company now expects to post adjusted EPS of $8.25 to $8.35, up from $8.20 to $8.30, on constant-currency sales growth of 8%-9% (up from prior guidance of 6%-8%).

Third-quarter adjusted EPS are forecast in the $2.07 to $2.11 range, on constant-currency sales growth of 7%-9%, Holland said.

The strong results sent BCR shares up 0.2% today to $147.29 apiece as of about 10 a.m. Eastern.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: 2014, C.R. Bard, Peripheral, Q2

In case you missed it

  • Organ-chips could streamline drug development, but hurdles remain
  • Ivermectin not supported for mild COVID-19, study says
  • ControlRad gains clearance for imaging tech to sell to Boston Sci
  • Capsule lands Frost & Sullivan award for remote ventilator monitor
  • Philips debuts AI-enhanced imaging platform
  • Pulmatrix completes $40M offering, updates product pipeline timetable
  • Medtronic launches IDE trial for AFib tech
  • Medtronic hiring Walmart exec to run its supply chain
  • An Overview of IEC 60601-1 3rd Edition, 2nd Amendment
  • Report: Permira eyeing LivaNova purchase
  • Amgen to acquire Five Prime Therapeutics for $1.9B
  • Medtronic wins city council approval for 42-acre campus in Colorado
  • Conformis dips 9% on Street-beating Q4 results
  • Becton Dickinson acquires smart medication device maker GSL Solutions
  • FDA clears once-daily ADHD capsule from Corium
  • Philips and Disney want to make MRIs easier for children: Here’s how
  • Origami Surgical gains FDA clearance for robotic suturing devices

RSS From Medical Design & Outsourcing

  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
    Frost & Sullivan today announced that it awarded Ambu with a 2021 Global New Product Innovation Award. Ambu received the award for its single-use flexible endoscopes that are designed to make the devices safe, affordable and accessible. It has aView and aBox all-in-one video displays that eliminate the traditional video endoscopy tower size and expense to be… […]
  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that could help repair and prevent further heart muscle damage after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling following a heart attack,… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS